Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of serious adverse eventsb · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) showed no clear difference in risk of serious adverse eventsb compared with neostigmine (any dose) (low certainty).
1 finding from 1 review
Adverse events Number of events · participants with acute or subacute low‐back pain
It is very uncertain whether back school changes adverse events Number of events compared with joint manipulation (very low certainty).
1 finding from 1 review
Adverse events Number of events · participants with acute or subacute low‐back pain
It is very uncertain whether back school changes adverse events Number of events compared with combined myofascial therapy and joint manipulation (very low certainty).
1 finding from 1 review
Adverse events Number of events · participants with acute or subacute low‐back pain
It is very uncertain whether back school changes adverse events Number of events compared with myofascial therapy (very low certainty).
1 finding from 1 review
Serious systemic adverse events · CNV in people with pathologic myopia
It is very uncertain whether anti‐VEGF changes systemic serious adverse events compared with control (very low certainty).
1 finding from 1 review
Serious adverse events (number) · people with major upper gastrointestinal, liver and pancreatic surgery
It is very uncertain whether enhanced recovery protocol changes serious adverse events (number) compared with standard care (very low certainty).
1 finding from 1 review
Side effects or other adverse events · patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (SAE; %) · adults with CMT1A
1 finding from 1 review
Adverse events: bone resorption · Children with decayed primary molar teeth
1 finding from 1 review
Preformed crowns for decayed primary molar teeth 2015 · Cochrane All outcomesSix months and four years
Bone resorption: one case at six months in a tooth treated with a veneer crown; no bone resorption at either the veneer crown or stainless steel sites at four-year follow-up (Analysis 3.2).
1 study · 11 participants
Very low
Intervention not reported
Adverse events: skin irritation · older people
1 finding from 1 review
Adverse events (Ardizzone 2003) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).
1 finding from 1 review
Serious adverse events(4 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: preterm delivery · women undergoing assisted reproduction
Intrauterine infusion/injection of autologous platelet‐rich plasma may leads to higher adverse events: preterm delivery compared with no intervention or placebo (low certainty).
1 finding from 1 review
Intervention not reported
Major adverse limb events (MALE) · people with intermittent claudication
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found